复方丹参注射液联合肝亚段动脉栓塞术治疗肝细胞癌临床疗效观察

The efficiencies of hepatic artery infusion with the liquid compound of Radix Salvia Miltiorrhizae and segmental hepatic artery chemoembolization in HCC

目的：探讨肝动脉灌注复方丹参注射液联合肝亚段动脉栓塞术治疗肝细胞癌的临床疗效.方法：对53例经病理学确诊的肝细胞癌患者行经肝动脉灌注复方丹参注射液和肝亚段动脉化疗栓塞术治疗.检测栓塞治疗前后肝功能、甲胎球蛋白（AFP）血液含量;应用Karnofsky评分标准评价治疗前后生存质量的变化,以1～3年生存率评价其临床疗效.结果：技术成功率100%,术后30 d死亡率为1.89%.51例（96.23%）患者Karnofsky评分术后增加10分以上,生存质量提高.1～3年生存率分别为79.25%、66.04%、43.40%.肝功能改善,甲胎球蛋白（AFP）血液含量降低.结论：肝动脉灌注复方丹参注射液联合肝亚段动脉栓塞治疗提高了肝细胞癌患者的生存期,生活质量改善.

Objective：To explore the clinical effect of hepatic artery infusion （HAI） with the liquid compound of Radix Salvia Miltiorrhizae（RSM） and subsegmental TACE for treatment of hepatocellular carcinoma （HCC）. Methods： Fifty-three patients with histologically proven HCC were treated with HAI with the liquid compound of RSM and subsegmental TACE. Factors including patient survival, liver function, biologic response （decrease in α-fetoprotein levels） and quality of life were assessed in this study. Results： HAI with the liquid compound of RSM and subsegmental TACE were effective in increasing patient＇s serum albumin and decreasing serum in γ-glubulin, ALT, AST, and AFP. The survival rates were respectively 79.25%, 66.04%, 43. 40% in 1 ～ 3 years respectively. HAI with the liquid compound of RSM might be associated with an improvement in patient quality of life. Conclusion： The combination therapy of HAI with the liquid compound of RSM and subsegmental TACE reinforces beneficial effects on survival and quality of life in patients with HCC.